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ABSTRACT 
 
Michael Wayne Henderson: Arsenic compromises the alveolocapillary barrier, facilitating 
bacteremia in a mouse pneumonia model 
(Under the direction of: Mike B. Fessler) 
 
 The greatest threat to public health regarding arsenic exposure is consumption of 
contaminated drinking water. Chronic oral consumption of inorganic arsenic has been linked 
with respiratory dysfunction as well as immunotoxicity. Here we examined the effects of 
consuming either of two concentrations of sodium arsenite (250 ppb, 25 ppm) via drinking water 
in a mouse model of bacterial pneumonia. Arsenic exposure did not alter recruitment of 
leukocytes to the airway upon bacterial infection, nor pulmonary clearance of bacteria, but was 
associated with increased dissemination to extrapulmonary tissues. Mice exposed to arsenic 
had intact bloodstream killing of bacteria, suggesting that the increased extrapulmonary 
bacterial burden in lung-infected mice derived from increased escape from the lung. Analysis of 
early events in lung-infected mice revealed that arsenic led to accelerated escape of bacteria 
from the alveoli, providing new evidence that chronic exposure to arsenic-contaminated drinking 
water disrupts the architecture of the alveoli, permitting pathogen escape into the bloodstream. 
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CHAPTER 1: INTRODUCTION 
 
Arsenic is a naturally occurring metalloid, widely dispersed within the earth’s crust and 
sediment. Many species of arsenicals exist in the environment and are classified as inorganic or 
organic depending on the combined elements. The main forms of arsenic relevant for human 
exposure are the inorganic pentavalent (arsenate AsV) and trivalent (arsenite AsIII) species. 
Humans are exposed to anthropogenic and natural sources through inhalation or through 
ingestion, likely the predominant route globally. Inhalation toxicity is usually caused by inhaling 
the manufactured species, arsenic trioxide, which is used in many industrial settings including 
coal combustion, glass manufacturing, smelters, and pesticide manufacturing facilities. 
Additionally, arsenic trioxide can be incidentally ingested by consuming runoff from wood-
preserving facilities or from pesticide-treated crops. However, most ingestion exposures 
worldwide are from consumption of drinking water from areas with naturally high levels of 
arsenic present in nearby rocks or soil. Inorganic arsenic is readily absorbed from the 
gastrointestinal tract [1], and undergoes a series of reductive and oxidative changes as well as 
methylation before ultimately being metabolized to dimethlyarsenate (DMAV) [2-5]. The 
intermediate metabolites methylarsonous acid (MMAIII) and dimethylarsinous acid (DMAIII) 
have been demonstrated to be more toxic than their inorganic precursors [6].  
 
In one of the most tragic ironies, the World Health Organization (WHO) and the World 
Bank installed groundwater wells in low income countries within the Indochina Peninsula as a 
measure of combatting death due to diarrheal diseases resulting from consumption of fetid 
surface water. These populations were inadvertently exposed to toxic levels of arsenic in their 
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drinking water due to contamination from the natural deposits within the earth [7-9]. Reports 
from 1995 [10, 11] enlightened the world that these populations were exposed to toxic levels of 
arsenic and described the disease state of the affected individuals, prompting several 
epidemiologic investigations that today serve as the predominant source for our understanding 
of patterns of arsenic-induced disease in humans. Prolonged consumption of arsenic-
contaminated drinking water in humans has been demonstrated to cause arsenical dermatosis 
(hyperpigmentation and scaly keratosis), skin cancer, bladder cancer, urinary tract cancer, and 
kidney cancer [12-19]. Arsenic was recognized as a carcinogen in 1980, and then formally 
classified as a Group 1 carcinogen by IARC in 2004/05 [20, 21]. Epidemiological data has also 
demonstrated a link between consumption of arsenic contaminated drinking water and vascular 
fibrosis, endothelial damage and leak [22-24], immune suppression [25-32], and bone marrow 
depletion [33-36]. Recent literature has also identified important associations of arsenic 
exposure in humans with chronic structural lung disease, including pulmonary fibrosis, 
bronchiectasis, and reduced lung function [37-39]. This is of particular interest given that it has 
been demonstrated in rodent studies of chronic oral arsenic exposure that the lung is second 
only to liver as the tissue that retains the greatest levels of arsenic [5, 40, 41], in particular 
dimethylated species [5, 42].  
 
In addition to its reported structural and functional effects on mucosal organs such as the 
lung, arsenic has been demonstrated to suppress immunity. Reports indicate reduced IgM and 
IgG producing plasma cells, inhibition of clonal T cell expansion and macrophage activity, and 
decreases in CD4+ splenic T cells and IL-2 [18, 43-46]. Suggesting that arsenic might 
compromise pulmonary immunity in particular, a recent report from Chile [47] provided 
epidemiologic evidence that individuals within a demarcated region who consumed arsenic-
contaminated drinking water over a period of ~14 years were twice as likely to die from 
tuberculosis (TB). In addition to this, another recent report corroborated that oral arsenic 
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ingestion compromises pulmonary host defense against influenza A virus in mice [48]. Despite 
these preliminary reports, however, most of the scant literature to date that has investigated 
potential roles for arsenic in immunity has used in vitro cell line exposures of uncertain 
physiologic significance or inhalational exposures to arsenic trioxide [49], a route and arsenic 
species of uncertain relevance to predominant global arsenic exposure.  
 
In this report, our objective was to test whether inorganic arsenic exposure via drinking 
water impacts pulmonary host defense against common bacterial pathogens that cause 
community-acquired pneumonia, using a mouse model and the predominant human exposure 
route. Our findings indicate that a 5 week exposure to arsenite does not substantially affect the 
pulmonary or circulating leukocyte repertoire, or the intrapulmonary innate immune response, 
including bacterial burden within the lung. However, infection in arsenic-exposed mice results in 
rapid bacterial dissemination, and our data suggest that host defense functions of 
extrapulmonary macrophages are sensitive to the effects of arsenic toxicity. We identified the 
likely cause of increased and accelerated bacteremia to be a deficiency in the alveolocapillary 
barrier that compromises pathogen compartmentalization.  
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CHAPTER 2: METHODS 
 
Reagents 
Sodium arsenite, (S7400) and cacodylic acid (DMAV) (C0125) were purchased from 
Sigma (St. Louis MO). Lipopolysaccharide (LPS)(#421) for in vivo use was purchased from List 
biologicals (Campbell CA), and Escherichia coli 0111:B4 LPS (L2630) (Sigma) was used for all 
in vitro experiments. Dulbecco’s modified eagle medium (DMEM)(11320-033) and phosphate 
buffered saline (PBS)(100-10049) was purchased  from Gibco (Gaithersburg MD). Fetal bovine 
serum (FBS) (S11150, Atlanta Biologicals, Flowery Branch GA) was used in all cell culture or ex 
vivo macrophage studies.  Baxter saline (BHL2F7124) was used as the delivery vehicle for all 
bacterial inoculations. 
 
Animals and arsenic dosing 
Female 7-8 week old and weighing 18–22g C57Bl/6 mice were obtained from the 
Jackson Laboratory and used in accordance with the Animal Welfare Act and the U.S. Public 
Health Service Policy on Humane Care and Use of Laboratory Animals after review by the 
Animal Care and Use Committee of the NIEHS. Four liter volumes of drinking water were 
prepared with 250ug/L (ppb) or 25mg/L (ppm) sodium arsenite freshly every two weeks for 
consumption ad libitum. Mice consumed 2-5mL of arsenic-containing water (or vehicle control) 
daily for 5-6 weeks prior to experimentation. Body weight, food consumption, and behavior were 
evaluated every 5 days. For the results indicated in Supplementary Figure 1, AIN 93 (D10012M) 
diet was purchased from Research Diets Inc. (New Brunswick NJ). These animals consumed 
the special diet for 2 weeks prior to, and throughout, the 5 week treatment.
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In vivo bacterial exposures 
Klebsiella pneumonia (2000 CFU) (ATCC 43816) or Streptococcus pneumonia (6.5-9 
x105 CFU); (ATCC 6303) were delivered to the lung via oropharyngeal aspiration following 
anesthesia using 4% isoflurane at 1.5L/min for experiments evaluating pathogenesis and 
dissemination. For analysis of systemic bacterial clearance, 3 doses of Klebsiella pneumoniae 
(960, 6200, or 92000 CFU) were injected intravenously, and tissues were collected 6 or 18 
hours later. Spleen homogenate and whole blood were serially diluted and plated onto tryptic 
soy agar (TSA) plates for Klebsiella pneumoniae or TSA with 5% sheep’s blood for 
Streptococcus pneumoniae and incubated overnight for bacterial quantification. 
 
Immunoblotting 
To evaluate markers of epithelial injury, bronchoalveolar lavage fluid (BALF) was 
collected and prepared as described in McElroy Dobbs (cite), with minimal modifications. In 
brief, 400ul of BALF samples were centrifuged at 100,000g for 2 hours at 4°C and the pellet was 
resuspended in 65ul Laemmli Sample buffer with 50mM DTT as the reducing agent, and boiled 
for 8 minutes at 100°C. Samples were run on a 10% sodium dodecyl sulfate (SDS) 
polyacrylamide gel, using prestained standards (1610374, BioRad, Hercules CA) for validation 
of molecular weight. Proteins were transferred to a nitrocellulose membrane using transfer 
buffer with 20% methanol. Antibody (AF3244, R&D Systems, Minneapolis MN) was used at 
.3ug/ml to detect mouse T1alpha /podoplanin. Detection was performed with a secondary 
antibody labeled at 800nm (925-32214, LiCor, Lincoln NE) and measured using an Odyssey Fc 
(LiCor). Quantification was performed using ImageStudio 5.0 (LiCor).  
 
Primary macrophage harvest 
Bone marrow-derived macrophages were prepared by culturing cells harvested from the 
femur and tibia of C57BL/6 mice in DMEM supplemented with 10% FBS. L929 cell supernatants 
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(in DMEM) were used as a source of growth factors and were added to the media at 25% of the 
total volume. Macrophages were cultured for 7 days at 37°C, humidified, with 5% CO2, with 
fresh media being added every 3 days; adherent cells were retained and enumerated prior to 
seeding for experimentation. Peritoneal macrophages were collected via peritoneal lavage 96 
hours after elicitation via injection of 2ml of 4% Brewer’s thioglycollate. Macrophages were 
counted, plated at 7.5e5 cells per well in DMEM + 10% FBS, and allowed to settle overnight 
prior to experimentation. Bone marrow derived macrophages were exposed to arsenite or 
DMAV ex vivo for 8 hours prior to additional treatments, unless otherwise noted. MTT assay 
(CT02, Millipore, Billerica MA) was performed according to the manufacturer’s 
recommendations following arsenic intoxication. For experiments analyzing gene expression, 
arsenic-treated macrophages were stimulated with 10ng/ml LPS (Sigma) for 2 hours in the 
presence of arsenic before mRNA was collected. A nitric oxide quantitation kit (40020, Active 
Motif, Carlsbad CA) was used to detect nitrate production in bone marrow derived macrophages 
following arsenic exposure and 24 hour stimulation using 1ng/ml LPS (Sigma). 
 
LPS exposures 
To assess early cytokine response, and neutrophil recruitment, mice were exposed to 
300ug/ml of aerosolized Escherichia coli 0111:B4 LPS (List Biologicals, Campbell CA) for 30 
minutes using a custom nebulizer chamber. BALF was collected immediately after euthanasia in 
volumes calibrated to overall body weight. BALF was centrifuged to pellet cells, and supernatant 
was collected and frozen at -80°C prior to analysis. Cell count and differential calculation was 
performed using Wright’s stain as described in Draper et al (ref). Lavage supernatant was 
analyzed via ELISA immunoassay for IgM (E90-101) and albumin (E90-134) (Bethyl) as 
markers of alveolocapillary barrier integrity and cytokines were measured via multiplex assay 
(M600009RDPD, BioRad). 
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Fluorescent assisted cell sort and quantitative microarray of respiratory epithelium 
Lungs are digested with porcine elastase (4.5U; E7885, Roche Diagnostics, St. Louis 
MO) and 100 U/ml DNase I (79254, Qiagen, Valencia CA). Cells in suspension are then filtered 
and sorted by FACS. The following antibodies were used: Pacific Blue/V450 streptavidin-
conjugated (560797, BD Biosciences, San Jose CA) secondary antibody was used to label 
biotinylated CD45 (553078, BD), CD31 (558737, BD), and CD34 (Lin)(119304, BioLegend, San 
Diego CA) expressing cells; APC-conjugated rat anti-mouse EpCam (17-5791-82, eBioscience, 
San Diego CA) and 7-aminoactinomycin D (A1310, Invitrogen, Grand Island NY). Cell isolation 
was performed using a FACS Aria II (Becton Dickinson, Franklin Lakes NJ) cell sorter for 
epithelial cells (Lin-EpCam+). Collected cells are stored in TRIzol (15596-018 Invitrogen) for 
RNA isolation.  
 
FITC –dextran permeability analysis 
Disruption of alveolocapillary barrier was evaluated by measuring leakage of FITC-
dextran (D3305, Life Technologies, Grand Island NY) from the airways into the bloodstream. 
FITC –dextran (3000MW) was dissolved into sterile saline and was introduced to the airspace 
through oropharyngeal aspiration (55ul, 5mg/kg) following completion of the arsenic-water 
exposure regime. Mice were allowed to recover for 1 hour prior to euthanasia via sodium 
pentobarbital. Blood (400ul) was collected by cardiac puncture into an ETDA-containing plasma 
separating column (365985, BD). Serial dilutions of plasma were loaded into a 96 well plate and 
analyzed for fluorescence intensity (FI) using a BioTek Synergy (Winooski VT) plate reader and 
485/528nm filter. 
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Electron Microscopy 
Lungs were fixed with 4% paraformaldehyde at 25cm H2O hydrostatic pressure and 
fixed for 24 hours as described in [50]. Left lung lobes were sectioned longitudinally at 1-2mm 
intervals and submitted in cassettes to the electron microscopy (EM) laboratory for transmission 
electron microscopy (TEM) processing and evaluation. Each lung sample was removed from the 
cassettes and further trimmed into 1mm3 cubes then processed in the automatic Leica® Tissue 
Processor using the routine TEM program. Following processing, the samples were embedded 
into six resin blocks. Each resin block was trimmed and sectioned at 700-800nm then stained 
with 1% Toluidine blue with subsequent examination by light microscopy. Based on the 
Toluidine blue-sections, two blocks for each animal were selected for thin sectioning (a section 
~70 to 90 nm or "gold"). The thin sections were placed on a 100-mesh Formvar copper grid then 
stained with uranyl acetate and lead citrate. The grids were examined on a FEI Tecnai 120KV 
(Hillsboro OR) transmission electron microscope. Digital photomicrographs of each mouse were 
taken and evaluated. 
 
RNA isolation and qPCR 
RNA was isolated by RNEasy kit (74104, Qiagen). Complementary DNAs (cDNA) were 
generated from 500 ng of purified RNA using TaqMan reverse transcription reagents from 
Applied Biosystems (Foster City, CA). Real-time PCR was performed in triplicate with Taqman 
PCR Mix (Applied Biosystems) in the HT7900 ABI sequence Detection System (Applied 
Biosystems). Predesigned primers for Cxcl10 (Mm00445235_m1), IL-1β (Mm00434228_m1), 
TNFα (Mm00443258_m1), and iNOS (Mm00440502_m1) were purchased from Applied 
Biosystems. Gene expression was normalized to GAPDH (Mm99999915_g1) and expression 
levels in untreated control samples were set as a value of 1.0. 
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Inflammasome induction 
Bone-marrow derived macrophages were exposed to arsenite at concentrations from 0-
2µM for 4 hours prior to and during 4 hours of exposure to 10ng/ml LPS. Following this, cells 
were washed once with phosphate buffered saline and fresh media ± inflammasome trigger 
(ATP- 1191, Calbiochem, Billerica MA; Nigericin- N7143, Sigma) was given for 1 hour. 
Supernatants were collected for ELISA analysis; values were normalized to total cellular protein.  
 
Statistical Analysis 
Statistical analysis was performed using Prism 6.0 software from Graphpad Software, 
Inc. Statistical significance was determined using the unpaired student’s t- test, analysis of 
variance (ANOVA), or Mantel-Cox log-rank analysis. Significance indicated as: *=P 0.01 - 0.05, 
**=P  0.01 - 0.001, ***=P 0.001 - 0.0001, ****=P <0.0001. Post- test for linear trend (Figure 3B) 
was used to evaluate dose-dependent effects of arsenic toxicity; significance in this study 
indicated as † P= <0.001.  
 
Works in progress: 
 
Cytokine analysis 
TNFα, IL-6, IL-10  ELISAs were purchased from BioLegend;  MMP9, IL-1β, TGF-β, and 
GM-CSF ELISAs were from R&D Systems. All were used according to manufacturer’s 
instructions. Bio-Plex Pro mouse 23-plex assay (M600009RDPD, BioRad) was used to evaluate 
cytokine production in lavage fluid. 
 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded mouse tissues were deparaffinized and rehydrated.  
Antigen retrieval was performed with heat and pressure in a decloaking chamber, using 10 mM 
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pH 6.0 1X Antigen Decloaker citrate buffer retrieval solution (Biocare Medical, Concord, CA).  
Endogenous peroxidase was blocked with 3% hydrogen peroxide.  The sections were incubated 
with 10% normal donkey serum (Jackson Immunoresearch Laboratories, Inc., West Grove, PA) 
for 20 minutes, followed by the avidin-biotin blocking kit (Vector Laboratories, Burlingame, CA).  
The sections were incubated with Caspase-3  (Catalog#CP229C, Lot#102312, Biocare Medical, 
Concord, CA ) polyclonal primary antibody and an equivalent dilution of normal rabbit IgG 
(negative control; Jackson Immunoresearch Laboratories, Inc., West Grove, PA) for 60 minutes 
at 1:100 dilution.  Sections were incubated with biotin-sp-conjugated donkey anti-rabbit 
secondary antibody (Vector Laboratories, Burlingame, CA for 30 minutes at 1:500 dilution and 
Vectastain Elite ABC reagent, RTU for 30 minutes.  Antigen-antibody complex was visualized 
using  DAB (Dako Corp., Carpinteria, CA) for 6 minutes. The sections were counterstained with 
hematoxylin, dehydrated, cleared and coverslipped. 
 
Transepithelial electrical impedance assay 
A549 lung epithelial cells were cultured to confluency onto proprietary gold-plated 
chamber slides (8W10E+; Applied Biophysics). Monolayer permeability was measured using an 
electrical substrate impedance sensing system (ECIS; Applied Biophysics, Troy NY) as 
described in (Imani Singh HSP 27).  Once resistance stabilized between 1000-1500Ω, fresh 
media with 0, 0.625, or 1.25um sodium arsenite or the methylated arsenical cacodylic acid 
(DMAV). Application of 2000-3000Hz cycles was used to measure barrier function, and 
resistance was measured over 72 hours. These data report cell-cell junction, and not cell-matrix 
adhesion. All experiments were repeated 5 times; data are normalized to the average value of 
the resistance of media only cells. 
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CHAPTER 3: RESULTS 
 
Minimal impact of oral arsenic on steady state lung and circulating immune cell 
populations 
Both chronic and acute arsenic exposure through consumption of contaminated drinking 
water may cause bone marrow depression [51], leading to pancytopenia. Substantial in vitro 
information indicates that inorganic arsenic is immunotoxic [52-54], and in vivo when 
administered IT [55-57] or inhaled [58, 59]. However, there is limited information describing the 
immune composition within the lung following oral consumption of arsenic. To evaluate the 
resident immune cell populations in the lung, as well as hematopoietic effects in our model, we 
exposed 7 week old female mice to doses of 0, 250ppb, or 25ppm arsenic (sodium arsenite), for 
5 weeks ad libitum in the drinking water for 5 weeks. Steady state alveolar leukocyte numbers 
and populations were defined by collecting bronchoalveolar lavage fluid (BALF) from arsenic-
exposed animals (Figure 1). Animals receiving 25ppm arsenic had significantly more leukocytes 
in the BALF compared to animals receiving water alone (1A). However, differential analysis of 
leukocyte populations did not reveal significant changes among the treatment groups (1B). 
While previous studies have demonstrated increased rates of apoptosis in alveolar 
macrophages [60], these experiments analyzed cells exposed ex vivo. We further examined 
these animals using a complete blood count analysis, to determine if circulating leukocyte 
numbers or composition was significantly altered following arsenic exposure (1C). Animals 
receiving arsenic in their drinking water had an apparent dose-dependent effect on number of 
circulating monocytes, but these changes fell short of statistical significance (1D). These results
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provide evidence for arsenic causing decreased numbers of circulating leukocytes, but suggest 
that leukocyte numbers within the alveolar compartment may be ‘protected’ from this effect.  
 
 
 
Figure 1: Consumption of arsenic drinking water has a modest effect on pulmonary, but not 
circulating leukocytes. Seven week old female C57Bl/6 mice were exposed ad libitum to 
drinking water containing sodium arsenite (0-green; 250ppb-red; 25ppm-blue) for 5 weeks prior 
to analysis. A) Total leukocyte numbers recovered from BALF. B) Leukocyte differential from 
BALF indicates percentages of macrophages, lymphocytes, or neutrophils across treatment 
groups. C) Total white blood cell count per microliter (μl). D) Complete blood count (CBC) 
analysis of exposure groups indicates percent differences in the major populations of circulating 
leukocytes. *=P 0.01 - 0.05. 
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Effect of oral arsenic on leukocyte recruitment to the microbially exposed airway 
To determine if respiratory host defense functions remained intact following arsenic 
exposure, animals were exposed to 2000 CFU of the Gram-negative bacterium, Klebsiella 
pneumoniae, and then the host cellular immune response in the airway was quantified 24 hours 
later (Figure 2). Total white blood cell numbers in the airspace were not statistically different 
across the treatment groups (2A). Additionally, no significant quantitative differences were 
evident in leukocyte subpopulations within the BALF under any treatment (2B). Consistent with 
this, we did not detect any differences in complete blood count analysis across arsenic 
treatment groups (2C-D). To test the generalizability of these findings, we also infected arsenic-
treated mice with the Gram-positive bacterium Streptococcus pneumoniae (6.5e5 CFU). 
Similarly, we observed no differences in the total number of BALF leukocytes (2E). These data 
indicate that oral arsenic, under these exposure conditions, does not affect immune cell 
recruitment to the lung upon infection.  
 
Accumulation of leukocytes in the airspace 24 hours post-infection is not a simple 
readout of the primary host response, but is rather a dynamic readout that is sensitive to 
secondary feedback from earlier time points such as early clearance/overgrowth rates of 
bacteria in the airspace in response to host defense in the first hours after infection. In order to 
isolate the effect of oral arsenic on the primary innate immune response in the airway more 
directly, we simplified our challenge model by using aerosolized E. coli LPS (300ug/ml for 30 
min) instead of live bacteria. BALF was then collected 24 hours post-exposure for counting of 
airway leukocytes. Under these conditions, mice exposed to 25 ppm arsenic, but not those 
exposed to 250 ppb arsenic, had a modest, but statistically significant increase in alveolar 
leukocyte number (2F). These data suggest that arsenic consumption had no effect on 
recruitment of immune cells into the lung environment upon bacterial infections. However, a 
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moderate increase of leukocyte recruitment, seen only at the 25ppm dose, was observed in 
response to LPS.  
 
Figure 2: Responding immune cell composition is not significantly altered following respiratory 
challenge. A) Total leukocyte numbers recovered from BALF after 24 hours K. pneumoniae 
infection. B) Leukocyte differential from BALF indicates percentages of macrophages, 
lymphocytes, or neutrophils across treatment groups. C) Total white blood cell count per 
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microliter (μl). D) Complete blood count (CBC) analysis of exposure groups indicates percent 
differences in the major populations of circulating leukocytes. E) Total leukocyte numbers 
recovered from BALF after 24 hours S. pneumoniae infection. F) Total leukocytes recovered 
from lavage fluid 24 hours after LPS inhalation. *=P 0.01 - 0.05. 
 
Effect of oral arsenic on bacterial clearance/compartmentalization during pneumonia 
To determine if arsenic impacts bacterial clearance, arsenic (or control) -exposed mice 
were infected intratracheally (IT) with Klebsiella pneumoniae (2000 CFU). Lung, spleen, and 
blood were analyzed for bacterial counts 24 hours after infection (Figure 3). We observed no 
significant differences in lung bacterial burden across the treatment groups. However, 
quantification of bacterial load within the circulation and the spleen indicated a significant 
increase in these tissues, indicating greater extrapulmonary bacterial dissemination (3A). 
 
Given that dissemination of Klebsiella sp. has been demonstrated to be influenced by 
many factors [61], we decided to infect animals with another human-relevant pathogen, 
Streptococcus pneumoniae. Following the 5 week arsenic exposure course, mice were infected 
IT with 6.5e5 - 1.87e6 S. pneumoniae for 24 hours. As before, lung, spleen, and blood were 
collected, processed, and plated for bacterial enumeration. Arsenic consumption did not affect 
the bacterial burden within the lungs. Similar to K. pneumoniae, infection with S. pneumoniae 
displayed a statistically significant dose-dependent trend (P= <0.001) increase in bacterial 
burden in peripheral tissues as arsenic concentrations increased (3B).  
Analysis of the standard chow NIH-31 used in our studies revealed that this diet contained 300-
400ppb of arsenic content (analysis did not determine speciation). Many dietary arsenicals, 
such as arsenobetaine and arsenocholine undergo metabolism different from arsenite or 
arsenate [21] and are considered non-toxic [62]. Nonetheless, we were concerned that this 
significant degree of background arsenic exposure might be confounding our results, so we 
repeated the study using an arsenic-free specialty research diet, maintaining dosing solely 
16  
through water consumption (not shown). This cohort was infected with K. pneumoniae as well. 
Exposure to arsenic via drinking water on this arsenic-free diet had a similar effect on host 
defense as observed on NIH-31 chow, with unchanged bacterial burden in lung, but increased 
burden in extrapulmonary tissues. These results suggest that the dietary arsenic exposure did 
not significantly affect bacterial burden. 
 
 
Figure 3:  
Enhanced 
extrapulmonary 
bacterial 
dissemination in 
arsenic-exposed 
mice. Seven week old 
female C57Bl/6 mice 
were exposed ad 
libitum to drinking 
water containing 
sodium arsenite (0-
green; 250ppb-red; 
25ppm-blue) for 5 
weeks prior to 
analysis. Mice were 
infected IT, and 
lavage fluid was 
collected 24 hours 
later. A) Log CFU 
Klebsiella 
pneumoniae 
recovered from 
tissues. B) Log CFU 
Streptococcus 
pneumoniae 
recovered from 
tissues.  ***=P 0.001 - 
0.0001, ****=P 
<0.0001; †=P <0.001. 
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Taken together, our findings demonstrated increased bacteremia in animals following 
consumption of arsenic-contaminated drinking water at 24 hours post infection. In order to test 
the physiological significance of this impairment in host defense, we conducted a survival study 
by infecting animals with a lower dose of K. pneumoniae (1500 CFU) after a 5 week exposure to 
oral arsenic or control water. We monitored them post-infection for 2 weeks, with continuation of 
their assigned arsenic/water exposure. Under these conditions, there was a numerical, albeit 
not statistically significant reduction in survival in arsenic-exposed mice (Figure 4).  
 
Figure 4: Effects of arsenic exposure on host survival following respiratory infection. Seven 
week old female C57Bl/6 mice were exposed ad libitum to drinking water containing sodium 
arsenite (0-green; 250ppb-red; 25ppm-blue) for 5 weeks prior to IT infection with 1500 CFU 
Klebsiella pneumoniae. Percent survival was calculated daily. 
 
Differential effect of oral arsenic on LPS response of intrapulmonary vs. extrapulmonary 
macrophages 
To evaluate for a possible difference in the effect of arsenic exposure on the innate 
immune response of lung-resident versus circulating macrophages, we dosed mice that had 
completed the 5 week arsenic exposure with aerosolized LPS (300ug/ml) or IP LPS (0.5mg/kg) 
and quantified the early cytokine response (Figure 5).Nuclear factor kappa B-dependent 
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cytokine response is one of the earliest quantifiable responses in response to LPS, including the 
production of tumor necrosis factor alpha (TNFα)[63]. TNFα promotes the inflammatory 
response, and is a key cytokine for activation of antimicrobial function. Measurement of 
cytokines in the airspace fluid serves as a readout of the local cellular response in the lung, 
while measurement in serum as a readout of the response in the extrapulmonary compartment. 
Production of TNFα in the LPS-exposed airspace is largely produced by alveolar macrophages; 
whereas, serum TNFα is thought to largely arise from production by liver macrophages (Kupffer 
cells) and splenic macrophages. Mice that were dosed with aerosolized LPS displayed no 
significant differences in production of TNFα within the BALF among arsenic treatment groups 
(5A). Consistent with this, alveolar macrophages harvested from mice that were exposed in vivo 
to inhaled LPS made equivalent levels of TNFα protein ex vivo across all water/arsenic 
treatment groups (5B). Conversely, mice injected IP with LPS showed a dose-dependent 
reduction in TNFα concentration within the bloodstream (5C). These data suggest that oral 
arsenic exposure has differential effects on intrapulmonary versus extrapulmonary 
macrophages, reducing the in vivo LPS responsiveness of the latter, but not the former.  
 
 
Figure 5: Arsenic-mediated suppression of cytokine response is compartment specific. Mice 
were dosed with LPS either IT (A,B) or IP (C). Concentrations of TNFα were measured in A) 
BALF; B) alveolar macrophages; C) serum. *=P 0.01 - 0.05,  ****=P <0.0001 
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To test the effect of oral arsenic on a readily accessible peripheral macrophage, we 
harvested peritoneal exudate macrophages from mice that had completed a 3 week arsenic 
exposure (250 ppb only) and studied them ex vivo (Figure 6). Macrophages were exposed to 
LPS and assayed for production of TNFα. We observed no significant differences in production 
of TNFα in response to two different concentrations of LPS (6A). In addition, peritoneal 
macrophages from were tested for their phagocytic function. FITC-labeled K. pneumoniae was 
used at an MOI of 5 and macrophages were permitted time for engulfment. Flow cytometric 
analysis revealed that macrophages from arsenic-exposed were significantly less phagocytic 
than those from mice consuming water alone (6B). To study arsenic effect on macrophage LPS 
signaling in an even more direct and reductionist model, we harvested bone marrow-derived 
macrophages (BMDM) and exposed them ex vivo to arsenic or DMAV (Figure 7). 
 
Figure 6: Immunotoxic effects on extrapulmonary macrophages following in vivo exposure. 
Seven week old female C57Bl/6 mice were exposed ad libitum to drinking water containing 
sodium arsenite (0-green; 250ppb-red) for 3 weeks prior to elicitation of macrophages using 
Brewer’s thioglycollate and macrophages were collected 96 hours later. A) Macrophages were 
exposed to LPS (or vehicle) prior to quantification of TNFα in supernatants. B) Phagocytosis 
percentage of heat-killed K. pneumoniae. ***=P  0.001 - 0.0001. 
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The intended goal of arsenic methylation during metabolism is to produce a compound 
that facilitates excretion [64, 65]. However, some methylated metabolites of arsenic have been 
demonstrated to be cytotoxic and cell-signaling disruptors [66]. Additionally, the lung has been 
demonstrated to retain the methylated metabolite DMAV [5, 40]. BMDM were exposed to 
arsenite or the metabolite DMAV for 8 hours prior to analyzing viability using an MTT assay to 
determine if metabolism of the parent arsenic or exposure to a methylated metabolite was 
cytotoxic (7A). Doses of 10, 5, and 2.5um arsenite caused significantly reduced viability, 
whereas no tested dose of DMA V caused decreased viability in the macrophages. 
Macrophages were cultured in non-cytotoxic concentrations of arsenic before stimulation with 
LPS and processing of mRNA for quantitative analysis of cytokine transcripts (7B). Recognition 
of LPS drives transcription of both MyD88-dependent and -independent cytokines depending on 
signaling from different subcellular compartments (plasma membrane vs. endosome), which 
have distinct biological effects. These data indicate that transcript expression of both MyD88 –
dependent and independent cytokines were suppressed at doses of 2uM; transcription of 
Cxcl10, was also decreased at the 0.5uM dose. We also analyzed transcription of nitric oxide 
synthase 2 (iNOS), an enzyme that generates nitric oxide (NO), a potent antimicrobial agent 
with a proven role against Klebsiella pneumoniae [67, 68]. Arsenic did not significantly affect 
LPS-mediated induction of iNOS in BMDM (7C). By contrast, total nitrate plus nitrite production, 
a surrogate measure for NO, was significantly reduced after exposure to non-cytotoxic doses of 
arsenic, suggesting a potential effect of arsenic either on protein-level expression or function of 
iNOS (7D). Tested concentrations of DMA V did not cause inhibition. Activation of these 
inflammatory and antibacterial processes has been demonstrated to contribute to host defense 
against K. pneumoniae [69]. 
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Figure 7: Arsenic-mediated cytotoxicity and inhibition of signal transduction and host defense 
functions. In vitro analysis of bone marrow-derived macrophaged (BMM) for viability and 
immune function following arsenic exposure. A) BMM were exposed to doses of arsenite or 
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dimethylarsinous acid (DMA V)for 8 hours prior to conducting a tetrazolium dye assay (MTT) to 
indicate viability. Doses pf 2.5 uM and higher caused significant decreases in the number of 
viable cells. B) Macrophages were exposed to 0, 0.5uM, or 2uM arsenite for 8 hours prior to the 
addition of 10ng/ml LPS or vehicle for 1 hour. Quantitative (ΔΔCT ) real-time polymerase chain 
reaction (qRTPCR) was performed for analysis of transcription of the cytokines Cxcl10, pro 
IL1β, TNFα. C) BMM were analyzed for activation of the antimicrobial iNos pathway. 
Macrophages were exposed to doses of arsenitefor 8 hours prior to LPS (10ng/ml) for one hour.  
did not reveal a significant arsenic-specific difference in transcript. D) Griess assay was 
performed after exposing BMM to doses of arsenite (0, 0.5, 1, 2) or DMA V (0, 0.5, 1, 2) for 8 
hours, then exposing cells to10ng/ml LPS for an additional 16 hours before quantifying nitrate 
production. E) BMM were exposed to doses of arsenic (0, 0.5, 1, 2) for 4 hours, and 10ng/ml 
LPS was added for a further 4 hours. Supernatants were removed media containined the 
inflammasome triggers ATP (2.5mM) or Nigericin (50, 25,10uM) for 30 minutes and mature IL1β 
was analyzed by ELISA. *=P 0.01 - 0.05, **=P  0.01 - 0.001, ***=P 0.001 - 0.0001, ****=P 
<0.0001.  
 
More recently, activation of the inflammasome, a large multiprotein complex that 
promotes the maturation of the inflammatory cytokines IL-1β and IL-18, has been shown to be a 
critical component of immunity against K. pneumoniae infection [70]. Arsenic–treated BMDM 
were exposed to NLRP3 inflammasome priming and triggering and evaluated for production of 
mature IL-1β (7E). Non-cytotoxic doses of arsenic significantly inhibited IL-1β production by the 
NLRP3 inflammasome. Taken together, our in vivo experiments provide evidence that oral 
arsenic exposure reduces the innate immune response of extrapulmonary macrophages, a 
finding that is corroborated by direct in vitro exposure of cultured macrophages. By contrast, of 
interest, the TLR4 response of alveolar macrophages does not appear to be susceptible to oral 
arsenic exposure, perhaps suggesting that the alveolus may be a ‘protected’ immune 
compartment in the context of systemic arsenic intoxication. 
 
Arsenic compromises integrity of pulmonary epithelial barrier 
Our experiments with K. pneumoniae lung infection, revealing markedly increased 
bacteremia in the face of intact pulmonary bacterial clearance (Figure 3) suggested at least 
three possible mechanisms of arsenic effect: i) compromised bloodstream killing of bacteria; ii) 
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increased permeability of the alveolocapillary barrier to bacteria; and/or iii) impaired 
intrapulmonary host defense at an earlier time point than assayed (allowing for increased early 
extrapulmonary dissemination). To address the first possibility, we repeated K. pneumoniae 
infection, but bypassed the lung, directly injecting the bacteria intravenously (IV) (Figure 8). In 
one experiment, arsenic-exposed mice were injected with K. pneumoniae IV and allowed 4 
hours of incubation time before collecting whole blood and spleen for bacterial quantification. 
Bacterial burden was not significantly altered in either tissue in arsenic-exposed mice (8A). A 
second experiment, designed to address the possibility that we had oversaturated the killing 
response with too high of an inoculum, was conducted using a lower dose and a longer 
response period (18h). Again, no difference in bacteremia or splenic bacteria was observed 
across arsenic treatment groups (8B). Taken together, these results indicate that, despite the 
depressed systemic TLR response observed in arsenic-exposed mice, arsenic does not 
appreciably compromise bloodstream killing of bacteria.  
 
Next, in order to evaluate the effectiveness of pulmonary host defense at earlier time 
points, arsenic-exposed mice were dosed IT with K. pneumoniae, and then lung and peripheral 
organs assessed for bacteria 12h later (Figure 9). Consumption of arsenic drinking water did not 
affect bacterial numbers in the lung at this time point, suggesting that arsenic does not facilitate 
early bacterial overgrowth in the lung. No bacteria were detected in the bloodstream of control 
(water-exposed) mice, suggesting that this time point precedes dissemination of bacteria from 
the lung in the normal state. Of note, however, 1 of 6 mice exposed to 250 ppb arsenic and 4 of 
6 mice exposed to 25 ppm arsenic (P<0.05) had detectable bacteremia.  These data support 
the premise that the increased dissemination observed at 24 hours may derive from increased 
permeability of the alveolocapillary barrier to bacteria.  
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Figure 8: Peripheral clearance is not significantly affected by arsenic. After the normal arsenic 
exposure regime, mice were infected (IV) with Klebsiella pneumoniae for 4 (6.2e3, 9.2 e4 CFU) 
or 18 (960 CFU) hours prior to tissue collection. Bacterial burden was calculated from whole 
blood and spleen for each dose. There were no significant differences in recovered CFU at 18 
(A) or 4 (B) hours after infection.  
 
Measurement of plasma proteins in lung lavage fluid is an established indicator of 
disruption of microvascular (endothelial) integrity in the lung [71, 72]. To evaluate if arsenic 
caused disruption of the alveolocapillary barrier, BALF was collected from animals following the 
5 week arsenic exposure regime, with or without subsequent exposure to aerosolized LPS, and 
analyzed for the presence of albumin or IgM, two established markers of pulmonary 
microvascular injury (Figure 10). Albumin (67 kilodalton, kDa) concentration within the BALF 
was not significantly changed by arsenic exposure, even when acute lung injury (ALI) was 
further promoted by LPS challenge (10A). Similarly, IgM (~970 kDa) levels were not affected by 
arsenic, and differences in LPS –induced injury were not evident across arsenic treatments 
(10B). These results argue against significant disruption of the pulmonary endothelial barrier, at 
least as indicated by plasma-to-alveolar translocation of protein markers 67 kDa or larger. 
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In order to evaluate for possible increased alveolar-to-plasma permeability in vivo, we 
measured plasma levels of CC16, an endogenous Club cell protein that is released into the 
airspace and whose levels in the plasma are an established indicator of pulmonary epithelial 
permeability [73] (Figure 11). BALF and serum were collected from mice completing 5 weeks of 
consumption of arsenic drinking water and analyzed via ELISA for CC16 concentration. Mice 
exposed to 25ppm arsenic had significantly greater amounts of CC16 in the serum, but not the 
airway (11A). These data suggest that arsenic facilitated translocation of a protein from the 
airway to the bloodstream, and indicating acute lung injury. 
Figure 9: Early analysis respiratory 
infection reveals accelerated bacterial 
dissemination. To evaluate the early 
immune response, i.e. neutrophil 
effectiveness, mice were infected (IT) with 
Klebsiella pneumoniae. Lung tissue and 
whole blood were collected 12 hours after 
exposure and were plated for bacterial 
enumeration (calculated as log CFU per 
ml). Differences in peripheral burden 
(25ppm dose).  
*=P 0.01 - 0.05 
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Figure 10: Effects of arsenic on pulmonary microvascular permeability. After the normal arsenic 
exposure regime, mice were infected (IV) with Klebsiella pneumoniae for 4 (6.2e3, 9.2 e4 CFU) 
or 18 (960 CFU) hours prior to tissue collection. Bacterial burden was calculated from whole 
blood and spleen for each dose. Bacterial CFU recovered at 18 (A) or 4 (B) hours after infection. 
 
Alveolar-to-plasma transit has been measured using a variety of probes, radioactive and 
non-radioactive [74]. We used an established method for testing respiratory epithelial 
permeability by assaying for plasma presence of an airway-introduced fluorescent small 
molecule [75]. To test translocation from the alveoli to the bloodstream in vivo, FITC-dextran 
(3000MW) was instilled IT, and then plasma analyzed for fluorescence intensity (Figure 11B). 
Mice receiving 250ppb of arsenic in their drinking water demonstrated significantly greater 
fluorescence in the plasma, indicating that FITC-dextran translocation was enhanced by 
arsenic. Fluorescence was also numerically, but not statistically higher in the 25 ppm arsenic-
exposed mice. To test more specifically for cytotoxic effects of arsenic on the alveolar 
epithelium in vivo, effects which might increase permeability, we performed western blot 
analysis of BALF for microvesicles containing T1α/podoplanin, an established marker of alveolar 
epithelial type I cell injury [76] (Figure 12A). Densitometry revealed that mice receiving 25ppm 
arsenic in their drinking water displayed significantly increased T1α signal within the BALF, 
(12B) suggesting injury to alveolar epithelial type I cells. To further investigate these findings, 
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we collected and fixed whole lung tissue from mice that had been exposed to water, 250ppb, or 
25ppm arsenic for 5 weeks, prior to analysis via electron microscopy (EM)(Figure 13). Animals 
exposed to 25ppm demonstrated multiple apoptotic type I pneumocytes (13A), significant 
swelling from the basement membrane, and multiple platelets coating damaged endothelial 
lining. Examination of tissue collected from animals exposed to 250ppb revealed no examples 
of apoptotic pneumocytes, but revealed moderate swelling beneath the alveolar epithelial and 
endothelial basement membrane, with focal collagen dispersal, and fewer attached platelets on 
the endothelial lining. Animals consuming water alone displayed no dying type I cells, had very 
few observable platelets, and predominantly showed a thin, smooth endothelial lining (13B). 
Taken together, our data suggested that greater dissemination of a respiratory pathogen was 
likely not due to pulmonary or extrapulmonary immune compromise, but rather to facilitated 
escape from the lung compartment to the periphery due to a disruption of the alveolocapillary 
barrier, with some detectable effects on both alveolar and endothelial cells. 
 
 
Figure 11: Indications of facilitated alveolar to circulatory transit after arsenic consumption. A) 
ELISA of Club cell protein 16 (CC16) from BALF and serum. B) Fluorescence intensity (FI) of 
plasma from arsenic-exposed animals after IT administration of 5mg/kg FITC-dextran. *=P 0.01 
- 0.05, **=P  0.01 - 0.001. 
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Figure 12: Consumption of arsenic drinking water causes damage to type I pneumocytes. A) 
Western blot of T1α (podoplanin) from vesicles present in lavage fluid. Results are 
representative samples from three independent experiments. B) Densitometric analysis of 
western blot image in A. *=P 0.01 - 0.05. 
 
 
 
 
Figure 13: Electron microscopy reveals evidence of disruption 
to the alveolocapillary barrier. A) Mice receiving 25ppm arsenic 
in their drinking water exhibited numerous apoptotic type I 
pneumocytes. B) Differences in alveolar endothelial lining 
among arsenic treatment groups.  
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Additional mechanistic investigations of effect of arsenic on pulmonary epithelium 
underway 
We will pursue possible molecular pathways that can impact alveolar cell fate using IHC, 
to potentially elucidate specific molecular mechanisms responsible for our cytotoxicity findings. 
Lung tissue sections are currently also being processed for immunohistochemistry. Sections will 
be stained for Ki-67, Caspase-3, γ-H2AXto evaluate for proliferation defects, cell death, and 
DNA damage, respectively. Additionally, dysregulation of MMP-9 has been identified as a 
biomarker for arsenic-mediated lung toxicity [77, 78], and tissues were evaluated for production.  
 
Arsenic has been demonstrated in vitro to disrupt proteins that maintain junctional 
adhesions between epithelial cells [79]. Preliminary analysis of expression levels in the lung of 
arsenic-exposed mice of genes such as Zona occludens (ZO1), junctional adhesion molecules 
(JamA, JamC), occludin (OC), and claudins (Cldn3, Cldn18) suggests that arsenic disrupts 
normal expression (data not shown). We intend to conduct a much longer in vitro exposure time 
course using the mouse alveolar epithelial line E10, and the human alveolar line A549. Cells will 
be maintained within a range of arsenic concentrations for 24 hours, 1 week, 2 weeks, or 3 
weeks. Fluorescent microscopy will be used to detect possible changes within the cell-cell 
adhesive proteins, and mRNA will be collected to determine differences in transcription. Electric 
cell-substrate impedance sensing (ECIS) will also be used to establish the permeability of these 
junctions to electrical current.  
 
Pathway-specific transcriptome analysis will be conducted using Nanostring to search 
for and quantify the alteration of additional genes that are affected by consumption of arsenic-
contaminated drinking water. Nanostring technology is a variation of the DNA microarray 
technology that is capable of quantitatively assaying transcript copy, without the need for signal 
amplification using PCR. We chose this technology due to its high sensitivity, necessary when 
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working with very low cell numbers. EpCam positive (CD31,CD34, CD45 negative) epithelial 
cells were collecting using flow cytometric sorting, and mRNA was isolated. The mouse 
PanCancer and Immunology (Nanostring) codeset was chosen to evaluate genes that are 
potentially responsible for the results found in our previous studies, as well as to elucidate early 
biomarkers of carcinogenesis due to inflammation, pneumocyte toxicity, and stressed repair 
systems.
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CHAPTER 4: DISCUSSION 
 
The guideline for arsenic concentration in drinking water was first established in 1942 by 
a standard provided by the U.S. Public Health Service. In 1974, Congress passed the Safe 
Drinking Water Act, urging the Environmental Protection Agency (EPA) to establish limits for 
inorganic chemicals within drinking water, and determining that the concentration of arsenic 
should be limited to 50 μg/L (ppb). This concentration was reevaluated based on new research, 
and was lowered in 2001 from 50 ppb to the current standard of 10 ppb [80]. These standards 
are upheld by law in the United States, yet globally, millions of individuals are exposed to doses 
exceeding 120 ppb [81-84]. Low income populations within the Indochina Peninsula are 
particularly susceptible to these exposure levels. Few published studies allow for direct 
comparison of dose-toxicity relationships between rodents and humans [4, 21, 40, 85-89]. 
Although our study used a 250 ppb dose that may be higher than encountered globally except 
for in rare circumstances, it is nonetheless a ~100-200-fold lower exposure than a large number 
of reports that have studied arsenic in rodent models, and certainly much shorter in duration 
than encountered in human populations. As the leading cause of death in low income countries 
with high arsenic exposure is lower respiratory infections, we aimed to use a tractable rodent 
pneumonia model system to determine whether consumption of arsenic-contaminated drinking 
water increases susceptibility to bacterial respiratory infections.  
 
To determine whether our drinking water dosing scheme compromises the immune 
response to respiratory bacterial infection, we first addressed the toxic effects of arsenic
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exposure alone. Our findings demonstrate that 250 ppb arsenic does not substantially affect 
pulmonary immune cell numbers, nor composition of the circulating leukocyte repertoire. This is 
in contrast to past studies that have used IT or inhalation delivery of arsenic in rodents, which 
have found reductions in the numbers of alveolar macrophages [55-57]. Of interest, we detected 
a slight, but statistically significant increase in total airspace leukocytes in mice exposed to 25 
ppm arsenic. This effect was most likely due to an increase in lymphocytes, though the increase 
in lymphocyte number in our study did not quite achieve statistical significance. Consistent with 
our finding, lymphocytes were recently reported to be selectively increased in the lungs of mice 
exposed to low levels of arsenic in drinking water [48]. 
 
In order to test the innate immune response to microbial challenge, we infected mice 
with Klebsiella pneumoniae and Streptococcus pneumoniae, two clinically relevant bacterial 
pathogens. We observed no differences in the number or type immune cells recruited to the 
lungs, nor a significant reduction in any type of leukocyte in the bloodstream. Similar studies 
using viral challenge also demonstrated no significant differences in the number or type of 
immune cells 36 hours after infection [48]. In order to quantify host defense function, we next 
quantified bacterial burden in the lung and peripheral tissues. Unlike earlier inhalation studies 
[49] and the aforementioned viral challenge [48], we found no significant differences in microbial 
number within the lung compartment among arsenic treatment groups, suggesting that oral 
arsenic does not compromise pulmonary host defense within this early time frame. By contrast, 
mice exposed to either 250 ppb or 25 ppm oral arsenic had marked increases in bloodstream 
and splenic bacterial load, indicating greater extrapulmonary dissemination of bacteria.  
 
Our experiments indicated that arsenic consumption increased the severity of the 
extrapulmonary dissemination, but had not determined the cause to be resultant from a failure in 
the lung compartment or the periphery. Other studies have demonstrated that ex vivo exposure 
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to inorganic arsenic to alveolar macrophages definitely compromised host defense functions 
[53, 56]. Yet we found no in vivo evidence for alveolar macrophage toxicity. These data 
provoked questioning the compartment-specific arsenic toxicity caused by oral exposure. We 
therefore conducted studies on peripheral macrophages using a dual exposure scenario: in vivo 
arsenic exposure and ex vivo stimulation; and in vitro exposure of primary cells. These studies 
demonstrated that the host defense functions peripheral macrophages directly exposed to 
arsenic, or its blood borne metabolites, were inhibited. To determine if this toxicity seen in vitro, 
would compromise peripheral bacterial clearance in vivo we bypassed the lungs by directly 
injecting bacteria into the bloodstream. Our results showed that arsenic exposure does not 
inhibit peripheral clearance of bacteria, and we began to investigate mechanisms of toxicity 
beyond immune suppression.  
 
Given that consumption of arsenic has been linked with peripheral microvascular 
disease [90-93], we postulated that arsenic exposure might disrupt the architecture of the alveoli 
which would permit bacterial escape into the bloodstream. Our findings agree with previous 
studies demonstrating that oral arsenic exposure does not cause leak of serum albumin into the 
alveoli, even after respiratory challenge [48]. However, we observed biomarkers of airway 
epithelial damage in the bloodstream, and performed a functional study in which we observed 
the transit of a fluor-labeled probe from the airways to the serum, indicating that alveolocapillary 
barrier integrity was reduced after consumption of oral arsenic. Furthermore, we presented 
evidence of type I pneumocyte damage, and cytotoxicity, thus disrupting the alveolar epithelial 
barrier and increasing permeability [94]. Electron microscopy revealed significant changes to the 
alveolar endothelium, specifically disorganization of the endothelial lining and platelet 
accumulation in the vasculature. Taken together, these results support that greater bacterial 
dissemination was likely caused by disruption of the alveolocapillary barrier, rather than the 
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immunotoxic effects of arsenic in our model. Moreover, our data suggest the possibility that 
epithelial breach further compromises barrier integrity. 
 
Type I pneumocyte toxicity was significantly detected at 25 ppm, but animals exposed to 
250 ppb exhibited significantly greater translocation of the FITC-dextran tracer. We suspect that 
lower doses of arsenic (sub 1 ppm) disrupt the proteins responsible for cell-cell junctions, 
permitting paracellular translocation. In vitro experiments using intestinal epithelial cells have 
described a similar scenario with compromised barrier integrity following arsenic exposure, 
though their rationale was dependent on increased levels of local TNFα [95]. Exploratory 
studies were conducted analyzing whole lung mRNA following arsenic exposure, and revealed 
differences in gene expression of claudins, junctional adhesion molecules, and occludin (not 
shown). Knowing that chronic arsenic exposure causes obstructive pulmonary diseases in 
humans (COPD) [37-39], we suspect that TGFβ, which has been demonstrated to play a major 
role in airway remodeling and COPD [96, 97], levels are increased in the BALF. We 
demonstrated that our higher 25 ppm dose caused apoptosis of pneumocytes, and efferocytosis 
of that debris could potentiate TGFβ production [98]. Additionally arsenic has been 
demonstrated to directly upregulate expression of TGFβ in certain cell types [99]. Therefore, we 
presume that in higher dose exposures, the remodeling response is engendered and would limit 
the transit of our probe. 
 
Compartmentalization of pathogens is a key function of the innate immune response. It 
can therefore be expected that compromised alveolocapillary barrier integrity would permit 
extrapulmonary dissemination, thus causing greater risk to the host. To our knowledge, this is 
the first report showing that consumption of arsenic in drinking water disrupts barrier function in 
vivo, and results in a worsened disease state upon infection. Many reports investigating the 
immunotoxicity of arsenic have suggested that exposed individuals would be at greater risk to 
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infection, and this work elaborates by describing significantly altered pathogenesis in a bacterial 
pneumonia model. Given the global health burden of arsenic drinking water contamination, we 
hypothesize that our results provide some rationale for the increased mortality due to respiratory 
infections in low-income populations of contaminated regions. 
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